» Articles » PMID: 3733227

Comparative in Vitro Activity of Cefpirome (HR 810) Against Gram-positive Isolates from Cancer Patients

Overview
Journal Infection
Date 1986 May 1
PMID 3733227
Authors
Affiliations
Soon will be listed here.
Abstract

The activity of cefpirome against gram-positive isolates from cancer patients was compared to that of currently available extended-spectrum cephalosporins. Cefpirome was active against methicillin-susceptible, coagulase-positive, and coagulase-negative staphylococci. It was the most active agent against streptococci belonging to Lancefield groups A, B and G and Streptococcus pneumoniae. 76% of enterococcal isolates were susceptible to cefpirome - far more than any of the other agents tested.

References
1.
Jones R, Thornsberry C, Barry A . In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin. Antimicrob Agents Chemother. 1984; 25(6):710-8. PMC: 185628. DOI: 10.1128/AAC.25.6.710. View

2.
Wade J, Schimpff S, Newman K, Wiernik P . Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med. 1982; 97(4):503-8. DOI: 10.7326/0003-4819-97-4-503. View

3.
Rolston K, Thirolf P, Ho D, Bodey G . Species dependent variability in the susceptibility of coagulase-negative staphylococci to various antimicrobial agents. J Antimicrob Chemother. 1985; 16(5):659-62. DOI: 10.1093/jac/16.5.659. View

4.
Wise R, Andrews J, Cross C, Piddock L . The antimicrobial activity of cefpirome, a new cephalosporin. J Antimicrob Chemother. 1985; 15(4):449-56. DOI: 10.1093/jac/15.4.449. View

5.
Fainstein V, Bodey G . Single-agent therapy for infections in neutropenic cancer patients. Am J Med. 1985; 79(2A):83-8. DOI: 10.1016/0002-9343(85)90266-9. View